Compare FT & VRXA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FT | VRXA |
|---|---|---|
| Founded | 1988 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.7M | 199.4M |
| IPO Year | N/A | 2025 |
| Metric | FT | VRXA |
|---|---|---|
| Price | $7.09 | $1.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 60.1K | ★ 226.7K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 7.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.95 | $1.04 |
| 52 Week High | $8.35 | $4.50 |
| Indicator | FT | VRXA |
|---|---|---|
| Relative Strength Index (RSI) | 36.55 | 36.74 |
| Support Level | $6.95 | $1.04 |
| Resistance Level | $8.32 | $1.99 |
| Average True Range (ATR) | 0.08 | 0.13 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 58.00 | 14.63 |
Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.